Parexel’s Post

#podcast Vin Singh, Founder & CEO of Bullfrog AI, discusses how AI is being used to improve the drug development process through a precision medicine approach that looks at a combination of genetic & non-genetic attributes to predict patient response to drugs. Bullfrog AI aims to reduce the failure rate in late-stage trials by enrolling the right patients in clinical trials. Through their partnership with the Johns Hopkins Lieber Institute for Brain Development, they use AI to analyze a unique dataset of post-mortem brains to discover new drug targets & improve clinical trial design. #BullfrogAI #AI #DrugDevelopment #ClinicalTrials #LieberInstitute #JohnsHopkinsUniversity  Bullfrogai.com https://lnkd.in/g_VVyq8E

Our latest episode of the Alldus, “AI in Action” Podcast features Drew Linsley from Operant Biopharma. Here Drew talks us through his journey and how Operant are using AI to autonomously design biological experiments, discovering and optimizing disease treatments. It’s another example of the groundbreaking work across the AI world. If you are a business leader doing innovative work in AI and would be interested in featuring on the podcast, we’d love to hear from you. #biopharma #artificialintelligence #aiinaction

Thanks, Daniel Levine, for this opportunity to talk about what makes Aulos Bioscience unique in our approach and how AU-007 is a promising therapeutic agent for cancer in the IL-2 space. What a great discussion, as always. #science #innovation

Dr. Na-Ri Oh and Ian Wendt here, and we couldn’t be more thrilled to share our latest The RealPharma Podcast episode with you. This time, we’re diving deep into the world of #ArtificialIntelligence / #AI in #Pharma with the incredible Dr. Andrée Bates. 🌟 Andree, the CEO of Eularis, is a true visionary in the field, and her insights are nothing short of groundbreaking. Whether you're a seasoned professional or just curious about AI's role in #healthcare, this episode is packed with valuable information. 🔍 We cover everything from: - How AI is revolutionizing drug discovery. - The ethical considerations we need to solve. - Real-world examples of AI making a difference in #patient outcomes. Andree’s passion for merging technology with healthcare is contagious, and we promise you’ll walk away feeling inspired and informed. 💡 Tune in to hear about the future of Pharma, the challenges we face, and the incredible potential that lies ahead. This episode is all about pushing boundaries and reimagining what’s possible. Listen here: https://lnkd.in/gMs9CkQg

“Driving Drug Discovery Efficiencies in Life Sciences with AI - with Anne Phelan of BenevolentAI” https://lnkd.in/eKVZwjGz On Emerj Artificial Intelligence Research’s ‘AI in Healthcare and Life Sciences’ podcast, BenevolentAI CSO Anne Phelan discusses the high costs of failed drug targets and how AI-enhanced techniques can mitigate these expenses. She explains how AI is revolutionizing how not only drugs are targeted, but also the patients that receive them: “I think the AI has given us a much more granular picture of stratification. There is a diagnostic component to the stratification. It's the extent of the symptoms that the patients suffer from, the extent of the inflammation in the colon. There is a kind of clinical diagnostic component to this, but actually, the AI is allowing us to layer on top of that much more molecular patient signatures. So that we can start to understand, in much more detail, why patients might be classed might be experiencing very severe symptoms. We can start to understand that at a much more molecular level.”

🚀 Exciting insights from the latest episode of the BioBreakthroughs podcast! 🌟 Host Jared S. Taylor dives into the complexities of clinical trial feasibility with experts Rohit Nambisan, CEO of Lokavant, and Christine Senn, PhD, SVP at Advarra. During this episode, Rohit and Christine discuss: 🔎 Clinical Trial Feasibility Challenges and the use of AI to tackle the daunting task of identifying patient populations for rare disease trials, emphasizing the need for precise patient density identification and low participant burden. 🏥 Site Perspectives and the importance of thorough feasibility assessments, and how rushed processes and incomplete information can lead to trial delays. 🤖 AI and Technology in Trials and it's transformative potential in predictive modeling and patient identification. Catch the full episode for a deeper dive into how AI and technology are revolutionizing clinical trials! 🎧 https://lnkd.in/dB2qMF9s #ClinicalTrials #AI #Biotech #Pharma #Innovation #HealthcareTech

Unlock the Future of AI-Driven Drug Discovery Iambic Therapeutics has made waves by raising an astonishing $100M dedicated to harnessing AI in drug discovery. Delve into a future where AI streamlines processes, trimming drug development costs by a remarkable 30%. Join Dr. Harvey Castro's MAIN Course for AIDE to navigate these monumental advancements. 📈 Step into the future of AI-empowered drug discovery.   Dive deep with the MAIN Course for AIDE:   🔗 https://lnkd.in/evk5HkKT  📰 Yearn for comprehensive insights into AI's role in healthcare? Subscribe to my newsletter:   🔗 https://lnkd.in/g8qMzXFu  ❓ How do you envision AI revolutionizing drug discovery timelines and processes?  #AI #DrugDiscovery #HealthTech #DrHarveyCastro #HealthcareInvestment  For an in-depth analysis, delve into:   🔗 Iambic's $100M for AI Drug Discovery https://lnkd.in/gm6UVVH8

#ICYMI 𝐄𝐢𝐠𝐡𝐭 𝐃𝐫𝐮𝐠𝐬 𝐚 𝐖𝐞𝐞𝐤, 𝐄𝐩𝐢𝐬𝐨𝐝𝐞 10 – 𝐌𝐚𝐜𝐡𝐢𝐧𝐞 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐀𝐈 𝐟𝐨𝐫 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐬𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐭𝐡𝐞𝐧 In this episode, we are lucky to be joined by two experts from the field of pharmacokinetic and pharmacodynamic modelling, Michael Neely and Jean-Baptiste Woillard. We hear about: 💡 The differences between traditional population pharmacokinetics and machine learning approaches in predicting drug exposure and optimizing dosing regimens. 💡Some advantages of ML approaches, including in handling nonlinear patterns. 💡The challenge of interpretability of results and dose recommendations from machine learning methods compared to traditional pharmacokinetic methods. 💡Which clinical contexts we will soon see machine learning derived models applied to clinical care. 💡The future of modelling and machine learning in pharmacology, including ethical considerations and the concept of augmented intelligence. 🎧 Tune in on your favorite podcast platform: Apple Podcasts 🔗 https://lnkd.in/gJd94qDh Google Podcasts🔗 https://lnkd.in/d65F7e8J Spotify 🔗 https://lnkd.in/gDixSbXx

Listen now to my recent #podcast🎙️ In this conversion with Kimberly Powell VP, & GM Healthcare #NVIDIA we explore how #AI, and in particularly #GenerativeAI, is transforming #healthcare and #drug discovery. https://lnkd.in/eJ2dFWGc

Check out the Alldus #AIinAction #podcast to learn more about how Alltrna applies #AI and #machinelearning to unlock #tRNA biology and scale #geneticmedicines for #rarediseases. #StopCodonDisease